FrenchWeb Highlights RebrAIn’s €3.7 Million Seed Funding for Parkinson’s Disease Innovation

frenchweb-highlights-rebrains-e3-7-million-seed-funding-for-parkinsons-disease-innovation

We are thrilled to share that FrenchWeb has featured RebrAIn for securing €3.7 million in seed funding to advance our AI-driven solutions for treating Parkinson’s Disease.

Led by Karista and supported by Nouvelle Aquitaine Co-Investissement, this funding will accelerate the international expansion of our innovative platform, OptimDBS, which aims to simplify and standardize Deep Brain Stimulation procedures. This significant investment underscores our commitment to enhancing patient outcomes and making neurosurgical treatments more accessible.

Read the full story here (in French).

An English translation by Google is available here.

Our latest public updates

Rebrain x Worldwide Dystonia Research Center

May 28, 2026

Partnership aims to develop next-generation data-driven models for personalized deep brain stimulation (DBS) targeting, expanding clinical applications from Parkinson’s disease and essential tremor to dystonia and severe pediatric dystonia with global scalability...

Rebrain unveils its identity: a strong vision for the future of assisted neurosurgery

May 21, 2026

At Rebrain, innovation has never been an end in itself. It has always been a means to improve the precision of neurosurgical procedures and to have a concrete impact on patients’ lives. Today, we are reaching a new stage of our development with the official launch of...

RebrAin 2025/2026: Expanding Reach, Driving Innovation

Jan 5, 2026

Transatlantic expansion RebrAIn’s focus for 2026 is expanding our reach to major neurosurgery reference centers in the US and Europe. Today, our top partner centers by volume are Duke University, University of Virginia (UVA), Pamplona and UCLA. These collaborations...

« Older Entries